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Abstract
Background: Childhood obesity is on the rise and is a major risk factor for type 2 diabetes later in life. Recent
evidence indicates that abnormalities that increase risk for diabetes may be initiated early in infancy. Since the
offspring of women with diabetes have an increased long-term risk for obesity and type 2 diabetes, the impact of
maternal metabolic abnormalities on early nutrition and infant metabolic trajectories is of considerable interest.
Human breast milk, the preferred food during infancy, contains not only nutrients but also an array of bioactive
substances including metabolic hormones. Nonetheless, only a few studies have reported concentrations of
metabolic hormones in human milk specifically from women with metabolic abnormalities. We aim to investigate
the impact of maternal metabolic abnormalities in pregnancy on human milk hormones and subsequently on
infant development over the first year of life. The objective of this report is to present the methodology and
design of this study.
Methods/Design: The current investigation is a prospective study conducted within ongoing cohort studies of
women and their offspring. Pregnant women attending outpatient obstetrics clinics in Toronto, Canada were
recruited. Between April 2009 and July 2010, a total of 216 pregnant women underwent a baseline oral glucose
tolerance test and provided medical and lifestyle history. Follow-up visits and telephone interviews are conducted
and expected to be completed in October 2011. Upon delivery, infant birth anthropometry measurements and
human breast milk samples are collected. At 3 and 12 months postpartum, mothers and infants are invited for
follow-up assessments. Interim telephone interviews are conducted during the first year of offspring life to
characterize infant feeding and supplementation behaviors.
Discussion: An improved understanding of the link between maternal metabolic abnormalities in pregnancy and
early infant nutrition may assist in the development of optimal prevention and intervention strategies and in the
protection of nutritionally vulnerable offspring who are at risk for obesity and diabetes later in life.
Background
Childhood obesity has emerged as an epidemic which is
reflected in the rapidly increasing rates of youth onset
type 2 diabetes [1-3]. Nutrition in infancy has been linked
with lifetime effects on the pathogenesis of obesity, insu-
lin resistance, and type 2 diabetes [4-6]. It has been pro-
posed that nutrition signals during the early postnatal
period may influence metabolic developmental pathways
and, thereby, induce permanent changes to metabolic
disease susceptibility [7,8]. Human breast milk is the
most preferred food during this early postnatal period
[9-11]. Several systemic reviews have reported that
breastfeeding has a protective effect on obesity [4,5] and
type 2 diabetes later in life [6]. The protective role of
breastfeeding against childhood obesity and type 2 dia-
betes may be explained by a number of potential deter-
minants including maternal metabolic abnormalities,
infant feeding behaviors, and biological components of
breast milk [12,13]. However, previously published large
observational studies have not assessed whether maternal
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nents are responsible for the observed associations of
breastfeeding with offspring obesity and type 2 diabetes.
Human milk contains not only nutrients but also an
array of bioactive substances [14,15]. These human milk
components function to transiently regulate tissue activ-
ities while the neonate’s endocrine system matures [16].
Bioactive substances involved in metabolic regulation
including adiponectin have been detected in human
milk [17-19], and it has been hypothesized that these
milk hormones may regulate growth and development
in infancy and influence the programming of energy bal-
ance later in life [17]. Interestingly, one of these milk
hormones, ghrelin, was reduced in the early postpartum
among women who had gestational diabetes mellitus
(GDM) [20]. In addition, mothers with diabetes often
experience delayed onset of lactogenesis II, defined as
the time to onset of copious milk secretion ≥72 hours
postpartum [21]. Taken together, these reports suggest
that the offspring of women with metabolic abnormal-
ities may be exposed to compromised early nutrition
and, therefore, are vulnerable to altered metabolic devel-
opment and increased susceptibility to metabolic disease
later in life.
Since offspring of women with obesity and diabetes
are at increased long-term risk for type 2 diabetes
[22,23], the impact of maternal metabolic abnormalities
on early postnatal nutrition and infant metabolic trajec-
tories is of considerable interest. Nonetheless, only a few
studies have reported concentrations of metabolic hor-
mones in human milk specifically from women with
metabolic abnormalities in pregnancy [20]. None have
investigated the associations of metabolic milk hor-
mones in colostrum (early human milk before onset of
lactogenesis II), from women with metabolic abnormal-
ities, with early metabolic development in infancy.
Maternal metabolic abnormalities and lactation
Women with obesity and/or diabetes often experience
poor lactation performance [21,24-28]. High prepreg-
nancy body mass index (BMI) was associated with
delayed onset of lactogenesis II [29]. Delayed onset of lac-
togenesis II among overweight and obese women was
explained by lower prolactin concentrations in response
to suckling at 48 hours postpartum compared to normal-
weight women [30]. Delayed lactogenesis II among over-
weight women in addition to excessive gestational weight
gain have been associated with the early cessation of
breastfeeding [27,31,32]. Studies which investigated milk
composition of women with type 1 diabetes reported that
the early milk samples had altered lactose, citrate, and
total nitrogen concentrations [33,34]. However, these stu-
dies were limited by small sample sizes which precluded
adjustment for potential confounding variables including
delivery complications, maternal behavior, and socioeco-
nomic status (SES). In addition, these studies did not
investigate concentrations of milk hormones that might
be involved in metabolic regulation.
Maternal metabolic abnormalities, breastfeeding and
childhood obesity
Although maternal metabolic abnormalities have been
documented to affect offspring metabolic status [22],
only a few studies have examined the impact of neonatal
feeding practices by women with metabolic abnormalities
on subsequent offspring obesity or diabetes [35,36]. In a
study from Germany, infants were provided with human
milk from their mothers with diabetes or donor human
milk from women with normal glucose tolerance [35].
Children who consumed a higher amount of human milk
from mothers with diabetes during the first week of life
were more likely to have a higher % relative body weight
at 2 years of age [35]. Neither ingestion of human milk
from women with diabetes during the first 2 to 4 weeks
of life nor the duration of breastfeeding had an indepen-
dent influence on risk of childhood overweight after
adjusting for neonatal feeding practice during the first
week of life [36]. The authors, therefore, concluded that
the first week of life was a critical window for nutritional
programming of offspring who ingested milk from
mothers with diabetes. Human milk composition during
this first week of life, however, was not reported in this
study. Therefore, it is unknown which components in
human milk contributed to this difference.
Metabolic hormones in human breast milk
In addition to nutrients, human milk contains bioactive
substances including metabolic hormones [14]. A num-
ber of metabolic hormones, including leptin, adiponec-
tin, and ghrelin [15,18,19,37-40], have been detected in
human milk. In serum, these hormones regulate energy
balance [41,42] and obesity-induced inflammatory sig-
naling pathways that contribute to type 2 diabetes [43].
Although several reports have been published on human
milk leptin [15,37,44,45], limited information is available
on whether milk leptin concentrations vary from women
across a spectrum of metabolic abnormalities in preg-
nancy, ranging from normal to obese/insulin resistant to
the full range of glucose tolerance in pregnancy. Previous
population-based longitudinal reports on the association
of milk adiponectin with offspring anthropometric mea-
sures did not provide detailed metabolic characteristics of
mothers nor did they study milk composition specifically
in colostrum [46,47]. One study reported that ghrelin
concentration in colostrum was reduced among women
who had GDM, but the difference was normalized and
not observed in mature milk [20]. This study, however,
was conducted in a small sample size and therefore the
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size. In addition, women who are obese and/or have dia-
betes are known to experience delayed onset of lactogen-
esis II [21,27]. Hence, offspring of mothers with metabolic
abnormalities may be exposed to compromised early
nutrition due to a lack of accessibility to human milk and/
or to an altered composition of human milk (Figure 1).
With emerging evidence indicating that metabolic hor-
mones are present in human milk, the impact of milk
hormones on the early metabolic regulation and potential
programming of energy balance requires an improved
understanding. Since adiponectin and leptin receptors
are present in the human gastrointestinal tract [48-51], it
is conceivable that milk hormones may have a functional
role locally via receptors in the stomach and intestine.
The immaturity of the neonatal gut barrier may also
allow for absorption and survival of various hormones
from human milk, which would allow milk hormones to
systemically influence metabolic development of the
infant. Goldman [52,53] and Koldovsky [54] have
reviewed characteristics of the neonatal gastrointestinal
tract that would allow for survival of human milk compo-
nents in this setting, including delayed production of
pancreatic proteases and gastric acid, the presence of
antiproteases and inhibitors in human milk, and the pos-
sible existence of higher permeability in the neonatal gut
to macromolecules. Disordered hormone concentrations
in human milk during a critical period may lead to sub-
optimal development of fundamental regulatory systems
in offspring [8]. For example, neural projection pathways
from the arcuate nucleus of the hypothalamus are
permanently disrupted in leptin-deficient mice [55].
Among these mice, leptin treatment in adulthood did not
reverse the defects, whereas the treatment in neonates
preserved the development of these pathways [55]. Opti-
mal milk hormone levels may promote the normal devel-
opment of hypothalamic pathways influencing energy
homeostasis throughout life. Only a few studies have
reported concentrations of metabolic hormones in
human milk specifically from women with metabolic
abnormalities in pregnancy [20]. None have investigated
the associations of metabolic milk hormones in colos-
trum, from women with metabolic abnormalities, with
early metabolic development in infancy. We aim to
address these knowledge gaps within the context of our
ongoing mother and infant cohort studies. This study is
conducted within a hospital setting which allows detailed
characterization of clinical events during pregnancy and
delivery in addition to lifestyle information collected
throughout late pregnancy and the first year postpartum
through scheduled contacts with participants. The pur-
pose of this report is to present the methodology and
design of the study investigating the impact of maternal
metabolic abnormalities in pregnancy on human milk
hormones and subsequently on infant development over
the first year of life.
Study objectives
Our overall aim is to investigate the impact of maternal
metabolic status in pregnancy on breastfeeding, human
milk composition, and infant development. The main
specific objectives are as follows:
Figure 1 Conceptual model.
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mones in colostrum of lactating women who had vary-
ing metabolic characteristics in pregnancy (i.e. a range
of adiposity, subclinical inflammation, insulin resistance,
beta-cell dysfunction, and glucose tolerance);
2. To compare metabolic hormone concentrations in
colostrum with concentrations in mature breast milk at
3 months postpartum;
3. To study the associations of milk hormones in
colostrum from mothers with varying metabolic charac-
teristics with infant metabolic characteristics (i.e. adipos-
ity and growth) over the first year of life; and
4. To investigate the associations of maternal meta-
bolic abnormalities with delayed onset of lactogenesis II,
defined as onset of copious milk secretion ≥72 hours
postpartum.
Methods/Design
Study setting and design
The current study is conducted within ongoing mother
and infant prospective cohort studies investigating early
events in the natural history of type 2 diabetes and vas-
cular disease. These studies are being conducted at
Mount Sinai Hospital and the Hospital for Sick Children
in Toronto, Ontario, Canada [56-59]. The current study
protocol was approved by the Mount Sinai Hospital
Research Ethics Board.
Standard obstetrical practice in Canada involves
universal screening for GDM in all pregnant women at
24-28 weeks gestation by a glucose challenge test
(GCT), wherein plasma glucose concentration is mea-
sured 1 hour after ingestion of a 50 g glucose load [23].
If the plasma glucose concentration is ≥ 7.8 mmol/L,
the patient is referred for a diagnostic oral glucose toler-
ance test (OGTT), in which plasma glucose values are
measured while fasting and then hourly for 3 hours fol-
lowing ingestion of 100 g of glucose. In clinical practice,
the OGTT would typically only be ordered if the GCT
were abnormal, whereas, in this study, the baseline preg-
nancy OGTT was completed in all participating women.
In addition to the baseline OGTT visit, women were
asked to participate in three follow-up visits and six tel-
ephone contacts from late pregnancy to one year post-
partum (Figures 2).
Study participants and recruitment
Pregnant women were recruited in outpatient clinic wait-
ing areas at Mount Sinai Hospital in Toronto, Canada,
a large tertiary care centre where over 7000 pregnancies
per year are followed. The inclusion criteria were singleton
or twin pregnancy, aged 20 years or older at the time of
recruitment, and intention to breastfeed. Women who
reported to have pre-existing diabetes were excluded.
Written informed consents were collected from 271
pregnant women. A total of 55 participants were with-
drawn from the study without completing the baseline
visit. Forty seven of 55 were unable to visit the study test-
ing unit during late pregnancy due to personal reasons
including difficulty taking time off from work in addition
to the time required for routine clinical obstetric visits.
Eight of 55 women initiated the baseline visit but were
unable to complete the 3-hour OGTT due to clinical rea-
sons including nausea and vomiting. A total of 216 partici-
pants completed the baseline pregnancy characterization
between April 2009 and July 2010.
Sample size justification
Sample size calculations were performed using PASS
(Kaysville, UT). We estimated that baseline pregnancy
characterization of between 210 and 220 women was
required to address our four main specific objectives
based on the following estimations.
To assess variation in metabolic hormones in colos-
trum from women with varying pregnancy metabolic
c h a r a c t e r i z a t i o n( o b j e c t i v e1 ) ,as a m p l es i z eo f8 2w a s
required to provide 80% power to detect a slope of 0.10
at the significance level of 0.05; this sample size would
allow detection of the correlation of 0.30. Based on pre-
vious literature, we expected that some women, especially
overweight/obese women might experience delayed onset
of lactogenesis II [26,29,31,60], and therefore might have
difficulty expressing colostrum samples. We considered
that 50% of our participating women would be in over-
weight/obese pre-pregnancy BMI categories (i.e. BMI >
25 kg/m
2) [56] and that 20% of normal weight women
and 35% of overweight/obese women would experience
delayed lactogenesis II [26,29,31,60]. After accounting for
15% loss to follow-up by the visit 2, a sample size of 135
was required to assess objective 1.
To test variation in metabolic hormone concentrations
in colostrum and mature milk (objective 2), we consid-
ered that 25% of lactating women might discontinue pro-
viding human milk before 3 month postpartum based on
previous local and national data [61,62]. After accounting
for additional 10% loss to follow-up from visit 2 to 3, a
sample size of 199 was required to assess objective 2.
To assess the impact of milk hormone concentrations
on infant metabolic characteristics over the first year of
life (objective 3), we accounted for additional 5% loss to
follow-up from visit 3 to 4. This provided a sample size
requirement of 210 women.
To study delayed onset of lactogenesis II from women
with varying metabolic characteristics (objective 4), we
aimed to complete pregnancy characterization for a
sample that would provide 80% power at a 0.05 signifi-
c a n c el e v e lt od e t e c tad i f f e r e n c ei nt h eo u t c o m eo f
delayed onset of lactogenesis II when the independent
variable (e.g. BMI) was increased to one standard
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an odds ratio of 1.8 in a logistic regression model with
adjustment for other independent variables that them-
selves account for an R-Squared of 0.3 (or 30%). After
considering a possible 20-30% overall loss to follow-up/
missing data rate from baseline to the first week post-
partum interview, we estimated that a sample size of
193-220 women was required to test objective 4.
Characterization of maternal metabolic status and data
collection
Data collection for this prospective cohort study occurs
during four study visits and six telephone contacts from
late pregnancy to one year postpartum (Figure 2). Fol-
low-up visits and interim telephone interviews are
expected to be completed in October 2011.
Visit 1 (baseline): late second and early third trimester of
pregnancy
Participating women underwent a 3-hour 100 g OGTT in
late pregnancy during which blood samples were drawn at
fasting and at 30, 60, 120 and 180 minutes post-load. The
OGTT on participating women in this study provides four
categories of maternal glucose tolerance in pregnancy [56]:
a. women with GDM defined as two or more of the
following [63]: fasting glucose ≥5.8 mmol/L, 1-hour
blood glucose ≥10.6 mmol/L, 2-hour blood glucose ≥9.2
mmol/L, or 3-hour blood glucose ≥8.1 mmol/L;
b. women with an OGTT indicating gestational impaired
glucose tolerance defined by exceeding only one of the
above glycemic thresholds [56];
c. women with an abnormal GCT but a normal
OGTT (i.e. none of the above criteria); and
d. women with a normal GCT and a normal OGTT.
Interviewers administered questionnaires to obtain
information on demographic, medical history, smoking
behavior, and physical activity using the Baecke instru-
ment [56,57]. Dietary intake was collected using a modi-
fied Block food frequency questionnaire (FFQ) in which
women were asked to recall usual intake during the sec-
ond trimester of pregnancy [64,65]. The Block FFQ has
been validated in several populations [66,67], including
women in Ontario, Canada [68]. The modified Block FFQ
focuses on intake during the previous 3-month time per-
iod and has been validated within a pregnant population
[69,70]. The questionnaire is designed to take approxi-
mately 30 minutes to complete and is self-administered.
Women’s height and weight were measured following
standardized anthropometric protocols [71].
Telephone contact: 36 weeks gestation
Participating women are contacted at 36 weeks gesta-
tion via a telephone call. Participants are instructed to
complete and return a modified Block FFQ recalling
their usual dietary intake during the third trimester of
pregnancy. Participants were provided with a FFQ in a
Visit 4
12mo
postpartum
Visit 3
3mo
postpartum
Visit 1
late
pregnancy
Parturition
Postpartum Pregnancy
Visit 2
0-3d
postpartum
Timeline:
P1
36wk
P2
3-7d
P3
6wk
P4
5mo
P5
7mo
P6
9mo
Telephone contacts (P):
Visits:
Figure 2 Schedule of four assessment visits and interim telephone calls from late pregnancy to 1-year postpartum.
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line visit for this purpose.
Visit 2: the first 3 days postpartum
Participating women and their neonates are visited in the
hospital within the first 3 days postpartum. Infant anthro-
pometry measurements are performed following standar-
dized procedures (NHANES III Anthropometric
Procedures) [72]. For length, infants are placed supine on
a measuring device, with a fixed headboard and a move-
able footboard (Seca, Hamburg, Germany), and measured
to the nearest 0.1 cm. Infants are weighed supine using an
electronic infant scale (Medela BabyWeight; Medela Inc,
Mississauga, Canada). For head and abdominal circumfer-
ence, a non-stretchable, plasticized measuring tape is used
to measure to the nearest 0.1 cm. The tape is wrapped
around the head of the infant superior to the eyebrows
and ears to assess the largest head circumference. For
abdomen circumference, the tape is wrapped around the
abdomen above umbilicus with the infant in the supine
position, and the expiration circumference is recorded.
Three measurements are performed for each. Delivery and
birth medical information of mothers and infants are
obtained from a hospital clinical database.
Colostrum samples are collected by hand expression
or an electric breastpump (Medela Electric Double
Breastpump; Medela Inc, Mississauga, Canada), which-
ever is preferred by a participant, during their hospital
stay. If the participating woman is unable to express
milk during the hospital stay, a home visit is conducted
by study personnel. Colostrum or an early human milk
donation is accepted up until day 7 of infant life (first
24 hours is considered as day 0).
Telephone interview: the first week of postpartum
On day 3 postpartum, mothers are contacted via a tele-
phone call (or visited in the hospital) to obtain informa-
tion on the timing of onset of lactogenesis II and early
postpartum infant feeding and supplementation beha-
viors. Mothers are asked to recall the nearest hour when
they started to feel their “milk-coming-in”. Specifically,
mothers are asked to recall the presence of a “tingling”
feeling in the breast, fullness, and swelling. This techni-
que for assessing onset of lactogenesis II by maternal
perception has been validated with test weighing [73]. If
the mother has not experienced lactogenesis II by day 3
postpartum, the women is contacted again on day 7
postpartum (± 2 days). If the woman reports no “milk-
coming-in” by day 7, the time to onset of lactogenesis II
is recorded as greater than 7 days postpartum.
Telephone interview: 6 weeks postpartum
Mothers are contacted at 6 weeks postpartum to obtain
information on infant feeding, specifically, exclusivity
and duration of breastfeeding and supplementation
behaviors. Mothers are asked to recall dates of introduc-
tion to infant formula, cow’s milk, and other fluid and
solids, if the event has taken place. If the mother reports
to have discontinued breastfeeding, the last breastfeed-
ing date and reasons for discontinuation are collected.
Visit 3: 3 months postpartum
Mothers and infants are invited to our research study
unit for a follow-up assessment at 3 months postpartum
(± 1 month). Mothers are asked to perform complete
breast expression using a double electric breastpump.
Mature human milk samples are collected for analysis.
Mothers complete a 2-hour 75 g OGTT. Interviewers
administer questionnaires asking about parental SES sta-
tus, paternal medical history, maternal postpartum phy-
sical activity/smoking, and infant feeding behaviors. A
self-administered modified 3-month Block FFQ is com-
pleted asking mothers to recall their food intake during
the first 3 months postpartum.
Infant anthropometric assessments are performed
using standardized anthropometric procedures
(NHANES III Anthropometric Procedures) [72], as
described for visit 2. In addition, skinfold thickness
measurements are performed using a skinfold caliper
(Harpenden skinfold caliper; John Bull British Indicators
Ltd, West Sussex, United Kingdom). Triceps, biceps,
suprailiac, and subscapular skinfold thickness are mea-
sured on the right side of the body under standard con-
ditions [74]. Validation studies have shown that skinfold
thickness measurements correlate with body fat assessed
by direct measurements including dual-energy x-ray
absorptiometry in infants [75] and children [76]. Three
measurements are performed for each anthropometric
variable.
Telephone interviews: 5, 7 and 9 months postpartum
Mothers are contacted at 5, 7 and 9 months postpartum
via a telephone call and asked to recall infant feeding
and supplementation behaviors as described for the
6 week phone interview.
Visit 4: 12 months postpartum
Mothers and infants are invited to the research study
u n i tf o raf o l l o w - u pa s s e s s m e n ta t1 2m o n t h sp o s t p a r -
tum. Mothers complete a 2-hour 75 g OGTT. Infant
anthropometric assessments are performed using stan-
dardized anthropometric protocols as described for the
3 month postpartum assessments. Infants are weighed
using an electronic infant scale appropriate for infants at
1-year (Seca, Hamburg, Germany). Infant feeding ques-
tionnaires are administered asking mothers to recall
infant feeding and supplementation behaviors.
Biochemical Procedures and Analyses
Maternal serum samples are processed and analyzed for
glucose and insulin concentrations according to estab-
lished protocols at the Banting and Best Diabetes Centre
laboratory, Mount Sinai Hospital, Toronto, Ontario,
Canada. Aliquots of serum/plasma are prepared and
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inflammatory markers, adipokines, and lipids). Insulin
sensitivity and beta-cell function are assessed by vali-
dated indices derived from insulin and glucose measure-
ments during the OGTT [77,78].
For human milk samples, whole milk samples are
divided into aliquots and stored at -80°C until analysis.
Before performing assays to measure metabolic hormone
concentrations, milk samples are sonicated to disrupt the
membrane vesicles and to allow immunodetection of
milk hormones because adipokines may be present in
milk fat globules [79]. Skim milk is prepared by centrifu-
gation to separate milk fat from the liquid phase.
Statistical Analyses
Distributions of continuous variables will be assessed for
normality, and transformations of skewed variables will be
used in statistical analyses as appropriate. Descriptive sta-
tistics for continuous variables will be summarized as
mean ± standard deviation or median (25
th-75
th percen-
tile) for variables with a skewed distribution. Categorical
variables will be summarized using proportions. Welch’s
modified t test or Chi-Square test will be performed for
continuous and categorical pairwise group comparisons as
appropriate. Bivariate associations of continuous variables
will be assessed using Spearman correlation analysis.
The following statistical analyses will be performed to
address the main objectives. Multiple linear regression
will be performed to assess study objectives 1, 2, and 3
with adjustment for potential covariates including
maternal lifestyle, SES, and medical history. The main
outcome and exposure variables and covariates for these
models, by objective, are presented in detail in Table 1.
For objective 1, the outcome variable will be metabolic
hormone concentrations in colostrum, while the expo-
sure variables will be maternal pregnancy metabolic
characteristics. For objective 2, the outcome variable will
be concentrations of metabolic hormones in mature
breast milk at 3 months postpartum, while the exposure
variables will be concentrations of metabolic hormones
in colostrum adjusting for covariates including maternal
metabolic characteristics at 3 months postpartum. For
objective 3, the outcome variable will be metabolic char-
acteristics of offspring during the first year of life, while
the main exposure variables will be concentrations of
metabolic hormones in colostrum adjusting for potential
covariates including maternal gestational metabolic
characteristics. This covariate adjustment will enable us
to assess the associations between milk hormones and
offspring metabolic characteristics independent of
maternal gestational metabolic variables. Other potential
confounders to be evaluated in these models are listed
in Table 1. For study objective 4, multiple logistic
regression will be performed with potential adjustment
for covariates including maternal lifestyle, SES, and
medical history. In these models, the outcome variable
will be defined as the presence of delayed lactogenesis
II; the main exposures will be maternal metabolic
abnormalities (i.e. obesity, hyperglycemia, insulin resis-
tance) (Table 1).
Discussion
We anticipate that this study will allow us to investigate
the impact of maternal metabolic characteristics in preg-
nancy on breastfeeding and infant development. An
improved understanding of maternal metabolic abnorm-
alities and infant nutrition may assist in developing pre-
vention and intervention strategies which will protect
vulnerable offspring exposed to suboptimal nutrition.
The main challenge of this study is that we have a
narrow biological window of time to collect colostrum
samples. We, therefore, have developed a computerized
notification protocol to alert the study personnel when
participants are admitted to the hospital maternity unit
and delivered their infants. However, it is expected that
some women may experience difficulty expressing and
Table 1 Summary of statistical analysis plans
Objective Statistical
technique
Outcome variable Main exposures Covariates
1 Linear
regression
concentrations of metabolic
hormones in colostrum (e.g.
adiponectin)
maternal metabolic characteristics
(e.g., glucose intolerance, insulin
resistance, obesity)
maternal lifestyle, SES, medical history
2 Linear
regression
concentrations of metabolic
hormones in mature breast milk
at 3 months postpartum
concentrations of metabolic
hormones in colostrum
maternal lifestyle, SES, medical history,
maternal metabolic characteristics
3 Linear
regression
metabolic characteristics in offspring
(e.g. infant growth, adiposity) during
the first year of life
concentrations of metabolic
hormones in colostrum
maternal lifestyle, SES, medical history,
maternal metabolic characteristics, infant
feeding/supplementation behaviors
4 Logistic
regression
delayed onset of lactogenesis II maternal metabolic characteristics
(e.g., glucose intolerance, insulin
resistance, obesity)
maternal lifestyle, SES, medical history
Abbreviations: SES, socioeconomic status.
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Page 7 of 10donating milk samples during the hospital stay. We have
considered this aspect into our sample size power calcu-
lation. In addition, we have also developed an additional
step within our protocol to visit mothers at home to
increase the opportunity to collect early human milk
samples within the first week postpartum. The strength
of the study is that it will yield novel insights into the
impact of maternal metabolic abnormalities on human
milk hormones and subsequently on the offspring’s early
metabolic trajectory. This study may assist in developing
optimal strategies to support the development of nutri-
tionally vulnerable offspring exposed to maternal meta-
bolic abnormalities and, therefore, reducing risk for
obesity, type 2 diabetes, and vascular disease later in life.
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